Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (81-90 of 150) with videos related to

Pageof 15
Sort By:
Scientific Reports|May 16, 2022
Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expressionToru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, et al.
Translational Lung Cancer Research|April 11, 2024
Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case reportShiting Xu, Takehito Shukuya, Shoko Shimamura, et al.
Global Health & Medicine|January 2, 2023
Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancerMasato Karayama, Yukihiro Mizoguchi, Yusuke Inoue, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, et al.
Investigational New Drugs|May 25, 2019
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursTakahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, et al.
Investigational New Drugs|February 9, 2021
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsNoboru Yamamoto, Toshio Shimizu, Kan Yonemori, et al.
Future Oncology (London, England)|May 13, 2020
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)Shun Yamamoto, Ken Kato, Hiroyuki Daiko, et al.
Gynecologic Oncology|April 21, 2026
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025)Aiko Ogasawara, Shiro Suzuki, Katsutoshi Oda, et al.
Cancer Science|December 18, 2007
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogelShinichi Kageyama, Shigehisa Kitano, Michiko Hirayama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGEYoshihiro Miyahara, Hiroaki Naota, Lijie Wang, et al.
Pageof 15

Showing results (81-90 of 150) with videos related to

Sort By:
Pageof 15
Scientific Reports|May 16, 2022
Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expressionToru Hanamura, Shigehisa Kitano, Hiroshi Kagamu, et al.
Translational Lung Cancer Research|April 11, 2024
Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer: a case reportShiting Xu, Takehito Shukuya, Shoko Shimamura, et al.
Global Health & Medicine|January 2, 2023
Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancerMasato Karayama, Yukihiro Mizoguchi, Yusuke Inoue, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2022
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, et al.
Investigational New Drugs|May 25, 2019
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumoursTakahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, et al.
Investigational New Drugs|February 9, 2021
A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsNoboru Yamamoto, Toshio Shimizu, Kan Yonemori, et al.
Future Oncology (London, England)|May 13, 2020
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)Shun Yamamoto, Ken Kato, Hiroyuki Daiko, et al.
Gynecologic Oncology|April 21, 2026
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025)Aiko Ogasawara, Shiro Suzuki, Katsutoshi Oda, et al.
Cancer Science|December 18, 2007
Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogelShinichi Kageyama, Shigehisa Kitano, Michiko Hirayama, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2005
Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and SAGEYoshihiro Miyahara, Hiroaki Naota, Lijie Wang, et al.
Pageof 15